**AISF**  
ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO  

**ROME, FEBRUARY 24th-27th, 2010**

**12th A.I.S.F. PRE-MEETING COURSE**  
"Liver Diseases, Life Style and Behaviour"  
Aula Magna, Università degli Studi di Roma “Sapienza” - P.le A. Moro, 5  
Course Directors: R. Bruno, Pavia and G. Missale, Parma

**43rd Annual Meeting of the Italian Association for the Study of the Liver - A.I.S.F.**  
Aula Magna, Università degli Studi di Roma “Sapienza” - P.le A. Moro, 5

**3rd A.I.S.F. POST-MEETING COURSE**  
"Reading Radiological Images in Liver Diseases"  
Auditorium, Centro Congressi Frentani - Via dei Frentani, 4  
Course Directors: F. Piscaglia, Bologna and P. Toniutto, Udine

---

**Preliminary Scientific Programme**

Wednesday, February 24th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30-10.45</td>
<td>Registration and Entry questionnaire</td>
</tr>
</tbody>
</table>
| 10.45-11.00 | Course Presentation  
R. Bruno & G. Missale |
| **Session I** | Liver: Obesity and NAFLD-NASH  
Chairpersons: P. Loria, Modena  
M. Persico, Naples |
| 11.00-11.20 | Obesity, morbidity and mortality  
A. Casini, Florence |
| 11.20-11.40 | New insights in NAFLD-NASH and Related Metabolic Diseases  
E. Bugianesi, Turin |
| 11.40-12.00 | Therapy in NAFLD-NASH and Related Metabolic Disease  
G. Marchesini Reggiani, Bologna |
| 12.00-12.20 | Metabolic effect of Bariatric Surgery  
S. Camastro, Pisa |
| 12.20-13.00 | Discussion |
| 13.00-14.00 | Lunch |
| **Session II** | Alcohol and Liver Disease: Recent Insights and New Directions  
Chairpersons: A. Benedetti, Ancona  
C. Loguercio, Naples |
| 14.00-14.20 | Alcohol Intake in 2009: Epidemiologic Trends  
E. Scafato, Rome |
| 14.20-14.40 | Acute Alcoholic Hepatitis (AAH)  
F. Caputo, Cento |
| 14.40-15.10 | Pharmacological Management of Alcoholism  
G. Addolorato, Rome |
| 15.10-15.30 | Discussion |
| 15.30-15.50 | 2009 Annual report: the state of the drug addiction problem in Europe  
G. Serpelloni, Rome |
| 15.50-16.10 | Substance Abuse and Liver Injury  
M. Cibin, Venice |
| 16.10-16.30 | Discussion |
| 16.30-16.50 | Break |
| **Session III** | Drug Addiction and Liver Injury  
Chairpersons: F. Piscaglia, Bologna  
M. Puoti, Brescia |
| 16.50-17.10 | Travel-Related Causes of Liver Diseases  
E. Brunetti, Pavia |
| 17.10-17.30 | Liver diseases: Toxicity of Herbal Medicine  
F. Menniti Ippolito, Rome |
| 17.30-17.50 | Coffee and Liver diseases  
C. Lavecchia, Milan |
| 17.50-18.10 | What should a patient with liver disease eat?  
M. Merli, Rome |
| 18.10-18.30 | Discussion |
| 18.30-19.00 | General Assembly I |
43rd Annual Meeting of the
Italian Association for the Study of the Liver - A.I.S.F.
Aula Magna, Università degli Studi di Roma "Sapienza" - P.le A. Moro, 5
Rome, February 25th-26th, 2010

Thursday, February 25th

08.30-10.00 Oral Communications
Chairpersons: C. Bolsano, L’Aquila
M. Guido, Padua

Time course of hepcidin response to oral iron test clarifies the role of HFE and TFR2 in iron sensing

Beta-globin mutations are associated with parenchymal siderosis and fibrosis severity in patients with nonalcoholic fatty liver disease

Improved in vitro HBV replication in HUH7 cell line transfected with full length circular closed HBV-DNA by modification of the Gunther’s method
D. Cavallone, P. Colombatto, F. Moriconi, A. Stabile, A.M. Maina, F. Bonino, M.R. Brunetto-Pisà, Milan

Successful isolation, culturing and differentiation of hepatic progenitor cells (HPC) from human foetal livers

Better sustained control of chronic genotype 1 HCV infections with PEG-IFN ALFA-2A than with PEG-IFN ALFA-2B treatment: results of daily clinical practice

Epidemiological changes of bacterial infections in cirrhotic patients: a current clinical problem

10.00-10.30 State-of-the-art Lecture
Introduced by: D. Prati, Lecco
Angiogenetic pathways in tumour development
F. Bertolini, Milan

10.30-11.00 Break and Posters view
Tutors: S. De Minicis, Ancona
L. Miele, Rome

11.00-12.00 General Assembly II

12.00-13.30 Oral Communications
Chairpersons: P. Almasio, Palermo
P. Andreone, Bologna

Reduced FGF-21 expression in liver of patients with nonalcoholic fatty liver disease
G. Soardo, D. Donnini, F. Favaretto, A. Boscaro, R. Vettor, D. Cappello, L. Domenis, C. Pagano, L. Sechi - Udine, Padua

Predicting mortality risk in cirrhotic patients since the first decompensation based on a new prognostic score: the AISF-EPASCO prospective multicentre study

Host genetic determinants in HCV-related mixed cryoglobulinemia
Spleen stiffness correlates with portal hypertension and increases the accuracy of detection of esophageal varices in HCV cirrhosis

Virtual touch assessment of liver cirrhosis in chronic liver disease during conventional ultrasound scanning

A reduced regulatory activity and predominance of the gamma-delta Vdelta1 subset characterise patients with HCV-related type 2 cryoglobulinemia

M. Angelico, Rome
Chairpersons: N. Caporaso, Naples A. Craxì, Palermo

Oral Communications
Chairpersons: F. Bonino, Milan G. Raimondo, Messina

Acute hepatitis C in haemodialysis patients: natural course and response to IFNα-monotherapy

Estrogen receptor β selective agonists exert anti-cancer activity on experimental intra-hepatic cholangiocarcinoma: an in vitro and in vivo study

Telaprevir (TVR) q8h or q12h combined with either Peginterferon (PEG-IFN, P) alfa-2a or alfa-2b and Ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C: Final results of the randomized, open-label, multicenter Phase 2 study C208
M. Colombo, M. Rumi, G. Carosi, M. Puoti, P. Marcellini, X. Forns, T. Göser, P. Ferenci, F. Nevens, J. Drenth, L. Serfaty, M. Beumont-Mauviel, G. Picchio - Milan, Brescia, Clichy (France), Barcelona (Spain), Köln (Germany), Wien (Austria), Leuven (Belgium), Nijmegen (The Netherlands), Paris (France), Mechelen (Belgium), Yardley (PA, USA)

Prevalence and risk factor of HBV infection among 4959 immigrants from non EU countries in Italy

Telaprevir (TVR) q8h or q12h combined with Peg-IFN α-2a or α-2b and ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C: Final results of the randomized, open-label, multicenter Phase 2 study C208
M. Colombo, M. Rumi, G. Carosi, M. Puoti, P. Marcellini, X. Forns, T. Göser, P. Ferenci, F. Nevens, J. Drenth, L. Serfaty, M. Beumont-Mauviel, G. Picchio - Milan, Brescia, Clichy (France), Barcelona (Spain), Köln (Germany), Wien (Austria), Leuven (Belgium), Nijmegen (The Netherlands), Paris (France), Mechelen (Belgium), Yardley (PA, USA)

Prevalence and risk factor of HBV infection among 4959 immigrants from non EU countries in Italy

Prevalence and risk factor of HBV infection among 4959 immigrants from non EU countries in Italy

Role of epithelial-mesenchymal transition in portal fibrosis development in fibropolycystic liver diseases (Congenital Hepatic Fibrosis and Caroli Disease)
S. Okolicsanyi, Padua

Telaprevir (TVR) q8h or q12h combined with Peg-IFN α-2a or α-2b and ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C: Final results of the randomized, open-label, multicenter Phase 2 study C208
M. Colombo, M. Rumi, G. Carosi, M. Puoti, P. Marcellini, X. Forns, T. Göser, P. Ferenci, F. Nevens, J. Drenth, L. Serfaty, M. Beumont-Mauviel, G. Picchio - Milan, Brescia, Clichy (France), Barcelona (Spain), Köln (Germany), Wien (Austria), Leuven (Belgium), Nijmegen (The Netherlands), Paris (France), Mechelen (Belgium), Yardley (PA, USA)

Telaprevir (TVR) q8h or q12h combined with Peg-IFN α-2a or α-2b and ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C: Final results of the randomized, open-label, multicenter Phase 2 study C208
M. Colombo, M. Rumi, G. Carosi, M. Puoti, P. Marcellini, X. Forns, T. Göser, P. Ferenci, F. Nevens, J. Drenth, L. Serfaty, M. Beumont-Mauviel, G. Picchio - Milan, Brescia, Clichy (France), Barcelona (Spain), Köln (Germany), Wien (Austria), Leuven (Belgium), Nijmegen (The Netherlands), Paris (France), Mechelen (Belgium), Yardley (PA, USA)

Telaprevir (TVR) q8h or q12h combined with Peg-IFN α-2a or α-2b and ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C: Final results of the randomized, open-label, multicenter Phase 2 study C208
M. Colombo, M. Rumi, G. Carosi, M. Puoti, P. Marcellini, X. Forns, T. Göser, P. Ferenci, F. Nevens, J. Drenth, L. Serfaty, M. Beumont-Mauviel, G. Picchio - Milan, Brescia, Clichy (France), Barcelona (Spain), Köln (Germany), Wien (Austria), Leuven (Belgium), Nijmegen (The Netherlands), Paris (France), Mechelen (Belgium), Yardley (PA, USA)

Telaprevir (TVR) q8h or q12h combined with Peg-IFN α-2a or α-2b and ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C: Final results of the randomized, open-label, multicenter Phase 2 study C208
M. Colombo, M. Rumi, G. Carosi, M. Puoti, P. Marcellini, X. Forns, T. Göser, P. Ferenci, F. Nevens, J. Drenth, L. Serfaty, M. Beumont-Mauviel, G. Picchio - Milan, Brescia, Clichy (France), Barcelona (Spain), Köln (Germany), Wien (Austria), Leuven (Belgium), Nijmegen (The Netherlands), Paris (France), Mechelen (Belgium), Yardley (PA, USA)

Telaprevir (TVR) q8h or q12h combined with Peg-IFN α-2a or α-2b and ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C: Final results of the randomized, open-label, multicenter Phase 2 study C208
M. Colombo, M. Rumi, G. Carosi, M. Puoti, P. Marcellini, X. Forns, T. Göser, P. Ferenci, F. Nevens, J. Drenth, L. Serfaty, M. Beumont-Mauviel, G. Picchio - Milan, Brescia, Clichy (France), Barcelona (Spain), Köln (Germany), Wien (Austria), Leuven (Belgium), Nijmegen (The Netherlands), Paris (France), Mechelen (Belgium), Yardley (PA, USA)

Telaprevir (TVR) q8h or q12h combined with Peg-IFN α-2a or α-2b and ribavirin (RBV, R) in treatment-naïve genotype 1 hepatitis C: Final results of the randomized, open-label, multicenter Phase 2 study C208
M. Colombo, M. Rumi, G. Carosi, M. Puoti, P. Marcellini, X. Forns, T. Göser, P. Ferenci, F. Nevens, J. Drenth, L. Serfaty, M. Beumont-Mauviel, G. Picchio - Milan, Brescia, Clichy (France), Barcelona (Spain), Köln (Germany), Wien (Austria), Leuven (Belgium), Nijmegen (The Netherlands), Paris (France), Mechelen (Belgium), Yardley (PA, USA)
Drug transporter gene polymorphism predicts renal tubular toxicity in patients with chronic hepatitis B on long-term adefovir and lamivudine combination
M. Viganò, F. Facchetti, P. Dongiovanni, L. Valenti, R. Soffredini, S. Fargion, M. Colombo, P. Lampertico - Milan

Friday, February 26th

08.30-10.00 Oral Communications
Chairpersons: P. Angeli, Padua
M. Rizzetto, Turin

HBsAg serum levels negatively affect HBV specific immune response
E. Loggi, F. Bihl, L. Micco, C. Cursaro, A. Gramenzi, F. Canoleta, C. Granieri, M. Bernardi, P. Andreone - Bologna, Geneva (Switzerland)

Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative and positive patients with chronic hepatitis B (study 102 and study 103)
M. Rizzetto, P. Marcellin, E.J. Heathcote, J. Sorbel, E. Mondou, J. Anderson, F. Rousseau - Turin, Clichy (France), Toronto (Ontario, Canada), Uludag Bursa (Turkey), Durham (NC, USA)

Heterogeneity of stem-like cells in hepatocellular carcinoma

Biomolecular expression of target receptors of calcimimetic agents in experimental liver cirrhosis: a new strategy to reduce portal pressure
G. Sansòè, M. Aragno, C.E. Tomasinelli, L. Valfrè di Bonzo, M. Parola, A. Smedile, M. Rizzetto - Turin

Recipient MTHFR C677T polymorphism predicts pre-transplant cirrhosis progression and survival after liver transplantation

Early use of mycophenolate mofetil is a major determinant of one year graft survival after liver transplantation: results from the Liver Match prospective cohort study
M. Angelico, T. Marianelli, A. Ricci, U. Cillo, S. Fagioli, A. Gasbarrini, M. Strazzabosco, A. Nardi, on behalf of Liver Match investigators. Hepatology & Transplantation Units of Italian Liver Transplant Programs

10.00-10.30 Break and Poster view
Tutors: P. Caraceni, Bologna
C. Rigamonti, Milan

10.30-10.45 Presentation of the A.I.S.F. prize for the best Italian paper in 2008
Chairperson: C. Ferrari, Parma

10.45-11.15 General Assembly III:
Final Report of A.I.S.F. Scientific Commissions and Study Groups
Chairpersons: A.I.S.F. Coordinating Committee

11.15-12.05 State-of-the-Art Lecture
Introduced by: L. Bolondi, Bologna
How to improve the Italian University system
M. Regini, Milan

12.05-13.05 Oral Communications
Chairpersons: U. Cillo, Padua
P. Lampertico, Milan

Withdrawal of prophylaxis against HBV in transplanted patients with undetectable intrahepatic total and ccc-DNA: clinical outcome after twenty months of follow-up

Platelet count/spleen diameter ratio compared to HVPG and transient elastography to predict severe portal hypertension in patients with liver cirrhosis
W. De Bernardi Venon, D. Bitetto, C. Fabris, P. Toniutto, M. Rizzetto, A. Marzano - Turin, Udine

Liver cancer stem cells might be identified by their low content of reactive oxygen species: implications for hepatic tumor treatment
Allograft expression of innate immunity genes influences liver fibrosis progression and acute cellular rejection in liver transplanted patients
Udine, Padua, Novara

Cholangiocarcinoma in Italy: a national survey on demographic and clinical characteristics, diagnostic modalities and treatment.

MicroRNA-221 targets Puma and sensitizes human hepatocellular carcinoma cells to doxorubicin treatment
F. Fornari, L. Gramantieri, M. Milazzo, Daniela Pollutri, G.L. Grazzi, M. Negrini, L. Bolondi - Bologna, Ferrara

Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial
O. Riggio, L. Ridola, S. Angeloni, F. Cerini, F. Fanelli, M. Merli, F.M. Salvatori - Rome

Young Investigators Awards
Presenters for the 2 best oral communications
Basic: M. Levrero, Rome
Clinical: V. Di Marco, Palermo

Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: results of a randomized controlled trial
O. Riggio, L. Ridola, S. Angeloni, F. Cerini, F. Fanelli, M. Merli, F.M. Salvatori - Rome

Cancer-Associated Fibroblast (CAF) Recruitment is Mediated by Paracrine Platelet-Derived Growth Factor (PDGF) Signalling in Cholangiocarcinoma
M. Cadamuro, L. Fabris, L. Moserle, G. Nardo, L. Dall’Olmo, M. Colledan, I. Franceschet, S. Indraccolo, L. Okolicsanyi, M. Strazzabosco Padua, Bergamo, New Haven (CT, USA), Milan

MicroRNA-221 targets Puma and sensitizes human hepatocellular carcinoma cells to doxorubicin treatment
F. Fornari, L. Gramantieri, M. Milazzo, Daniela Pollutri, G.L. Grazzi, M. Negrini, L. Bolondi - Bologna, Ferrara

The natural history of hepatic macroregenerative nodules developing in cirrhotic patients during surveillance with ultrasound (US)
A. Sangiovanni, C. Della Corte, M.A. Monini, M. Lavarone, S. Vavassori, R. Romeo, M. Fraquelli, A. Aghemo, M. Colombo - Milan

Cholangiocarcinoma in Italy: a national survey on demographic and clinical characteristics, diagnostic modalities and treatment.
POSTER SESSION
Thursday, February 25th

N. 1 Lack of CFTR affects the innate immunity of the biliary epithelium and determines a TLR4/NF-κκκκ-mediated inflammatory response
R. Fiorotto, R. Scirpo, C. Spirli, M. Trauner, M. Strazzabosco - New Haven (USA), Bergamo, Graz (Austria), Milan, Monza

N. 2 Pharmacological induction of prostate apoptosis response 4 (PAR-4) promotes apoptosis of cholangiocarcinoma cells

N. 3 A genome-wide DNA methylation study in monozygotic twins discordant for primary biliary cirrhosis

N. 4 UDCA up-regulates human placental OATP-A expression in intrahepatic cholestasis of pregnancy

N. 5 Progressive Familial Intrahepatic Cholestasis: detection of new mutations and unusual modality of transmission

N. 6 Intrahepatic renin-angiotensin system and liver cirrhosis: an updated reappraisal
G. Sansoè, M. Aragno, G. Tomasinelli, R. Mastrococla, M. Parola - Turin

N. 7 Multiple cycles of G-CSF administration to mobilize bone marrow-derived cells (BMC) in patients with end stage liver cirrhosis.

N. 8 Hepatic mitochondria obtained from 6-OHDA-lesioned parkinsonian rats exhibit decreased energy capacity and membrane potential

N. 9 Minimal hepatic encephalopathy (MHE): simplified diagnosis and relationship with the development of overt hepatic encephalopathy (OHE)

N. 10 Kupffer cells reduce liver immunopathology
G. Sitia, M. Iannaccone, L.G. Guidotti - Milan

N. 11 Hepatic vein transit time (HVTT) of II generation ultrasound contrast agent (USCA): new tool in assessment of portal hypertension. Preliminary results
L. Siciliani, A.R. Sorbo, L. Riccardi, M. Pompili, G.L. Rapaccini - Rome

N. 12 Relationship between small intestinal bacterial overgrowth and intestinal permeability in cirrhosis
E. Scarpellini, A. Cazzato, M. Gabrielli, M.E. Ainora, G. Gasbarri, V. Valenza, A. Gasbarri - Rome

N. 13 Predictors of outcome in cirrhotics admitted to intensive care unit (ICU); survivors exhibited significant rise of serum sodium levels and a fall in lactate levels at 48 hours

N. 14 Collagen proportionate area in assessing the amount of fibrosis in chronic liver disease: does high resolution compared to conventional image capturing and analysis alters its results?

N. 15 Unawareness of HBV infection in hospitalized patients in Southern Italy
N. 16 Acute B hepatitis after transfusion of red blood cells from a donor with occult hepatitis B virus infection
M. Spreafico, B. Foglieni, L. Raffaele, I. Guarnori, A. Berzuini, M. Andreoletti, A. Colli, D. Prati
Lecco

N. 17 Differential effects of pegylated interferon alpha therapy on innate and adaptive immune responses in chronic Hepatitis B

N. 18 The HBV-specific T cell function can be reconstituted in chronic HBV infection: implications for immune therapies

N. 19 Dynamic contrast enhanced ultrasound in monitoring HCC patients treated with sorafenib: preliminary results

N. 20 Altered Yin Yang 1/RAF-1 kinase inhibitory protein ratio as a possible molecular marker and therapeutic target in hepatocellular carcinoma

N. 21 Diagnostic yield and standardization of fine needle biopsy in the characterization of liver nodules in cirrhotic patients
A. Sangiovanni, M. Iavarone, S. Vavassori, R. Reati, C. Della Corte, M.A. Manini, M. Fraquelli, G. Ronchi, M. Colombo - Milan

N. 22 Contrast imaging techniques correlate with tumor grading in the diagnosis of hepatocellular carcinoma in cirrhotic patients under surveillance
M. Iavarone, A. Sangiovanni, M. Manini, L.V. Forzenigo, G. Ronchi, M. Colombo - Milan

N. 23 Rosiglitazone inhibits hepatocellular cancer cells growth and down-regulates Ruvbl-1: evidences of a PPARgamma-independent mechanism of cell growth inhibition

N. 24 IL28b/IFN-λ3 rs12979860 polymorphism in patients with end stage liver disease: relationship with the occurrence of HCC

N. 25 Small nodular lesions in cirrhotic livers: characterization with contrast enhanced ultrasound
A. Giorgio, A. Di Sarno, N. Farella, G. de Stefano, U. Scognamiglio, C. Coppola, V. Giorgio - Naples

N. 26 Transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma in cirrhosis: influence on portal hypertension

N. 27 Tumor infiltrating CD4 T cells and liver infiltrating proinflammatory T-cells as predictors of disease free survival after resection for HCC.

N. 28 P53 is regulated by Notch3 signalling via MDM2 in hepatocellular carcinoma
M. Minguzzi, C. Giovannini, L. Gramantieri, P. Chieco, K.B. Marcu, C. Mastroleo, F. Piscaglia, L. Bolandi - Bologna, Stony Brook (NY, USA)

N. 29 Cytokeratin 19: an immunohistochemical marker to early detect hepatocellular carcinoma with a more aggressive behavior
V. Franceschini, E.M.C. Tesini, L. Losi, M. Vandelli, M. De Santis, S. Kalleci, C. Vandelli - Modena

N. 30 Correlation between FIB-4, Liver stiffness and metabolic parameters in patients with HIV and hepatitis C virus co-infection.
R. Bruno, P. Sacchi, S. Cima, L. Maiocchi, S. Patruno, C. Klersy, G. Filice, C. Cammà Pavia, Palermo

N. 31 Sustained virologic response prevents the development of esophageal varices in compensated, child-pugh class a HCV-induced cirrhosis. A twelve-year prospective follow-up study
N. 32 HCV infection is associated with high comorbidity burden in Europe

N. 33 HCV contributes to induce hepatic steatosis through nuclear LXR receptor

N. 34 IL6 polymorphisms play a role in influencing the histological progression in patients with chronic HCV infection and normal transaminases

N. 35 An amplified T-cell regulatory activity identifies patients with normal transaminases but also advanced disease in HCV-related chronic liver disease

N. 36 Long-term follow up of patients with acute hepatitis C and spontaneous resolution

N. 37 Clues for different profiles of health-related quality of life in patients with alcohol vs. mixed etiology (alcohol plus HCV) liver cirrhosis

N. 38 Safety and efficacy of PEG-IFN/RBV therapy in patients with chronic hepatitis C and high titres of serum autoantibodies: a sub-analysis of the mist study
R. D’Ambrosio, M.G. Rumi, A. Aghemo, GM. Prati, R. Soffredini, M.F. Donato, S. De Nicola, M. Colombo

N. 39 A 3-months multidisciplinary lifestyle intervention reduces insulin resistance and improves NAFLD
F. Scaglioni, M. Marino, M. Malavolti, N.C. Battistini, S. Bellentani - Modena, Carpi

N. 40 Occult hepatitis B virus infection in patients with non alcoholic steatohepatitis (NASH)

N. 41 Intracellular generation of reactive oxygen species as a crucial requirement for directional migration of hepatic pro-fibrogenic cells

N. 42 The Bagnacavallo fatty liver score may predicts the presence of metabolic syndrome in a general population: the preliminary results of a large observational study (Bagnacavallo-study)

N. 43 Leptin reduces liver necrosis/apoptosis induced by ischemia-reperfusion injury in the rat, through activation of STAT-3 pathway
M. Carbone, M. Angelico, L. Campagnolo, C. Almerighi, C. Telesca, F. Riccobelli, S. Cucchiarelli, L. Baiocchi - Rome

N. 44 Semaphorin7a, a new player in hepatic fibrosis: an in vitro and in vivo study
S. De Minicis, C. Rychlicki, L. Agostinelli, L. Trozzi, C. Candelaresi, S. Saccomanno, R. Bataller, E. Juez, M. Marzioni, A. Benedetti, G. Svegliati-Baroni - Ancona, Barcelona (Spain)

N. 45 Transient elastography vs. NAFLD scoring system in the initial evaluation of patients with fatty liver
E. Ceriani, E. Cornetti, M.E. Burlone, S. Fangazio, C. Smirne, M. Leutner, P. Toniutto, C. Fabris, M. Pirisi - Novara, Udine

N. 46 A prioritization model for liver transplantation based on a dual waiting list: a prospective controlled study

N. 47 Transient elastography early predicts progressive recurrent hepatitis C after liver transplantation
C. Rigamonti, M.F. Donato, M. Fraquelli, F. Agnelli, G. Rossi, M. Colombo - Milan

N. 48 Transforming growth factor-β1 and endothelin-1 mRNA expression in liver cells exposed in vitro to cyclosporine or sirolimus
G. Occhino, E. Boccato, R. Minisini, P. Toniutto, C. Fabris, M. Pirisi - Novara, Udine
AISF
ASSOCIAZIONE ITALIANA PER LO STUDIO DEL FEGATO

N. 49 Fibrosis progression in non responders to antiviral treatment (AT) for HCV recurrence following liver transplantation (LT)

Friday, February 26th

N. 1 Multipotent stem cells reside in human extrahepatic bile ducts (hEHBDs) and can give rise to hepatocytes, cholangiocytes and pancreatic islet cells
V. Cardinale, Y. Wang, G. Carpino, M. Gatto, M. Mennini, M. Rossi, P. Berloco, E. Gaudio, L.M. Reid, D. Alvaro - Rome, Chapel Hill (NC, USA)

N. 2 Performance of transient elastography and non invasive markers of liver fibrosis in primary biliary cirrhosis
N. Cazzagon, L. Chemello, D. Martines, L. Cavalletto, V. Baldo, R. Lazzari, A. Floreni Padua

N. 3 Progenitor cell activation and liver repair is altered in Notch2- and RBP-Jk-defective mice exposed to cholestatic injuries.
R. Fiorotto, C. Spirili, R. Scirpo, T. Gridley, S. Huppert, B. Torsello, C. Ferrero, M. Strazzabosco - Yale (CT, USA), Bergamo, Milan, Bar Harbor (ME, USA)

N. 4 Can non-invasive methods predict esophageal varices in children with biliary atresia after Kasay operation?

N. 5 Adrenal dysfunction in cirrhosis: prevalence and impact on survival in nonseptic patients with ascites

N. 6 Neutral endopeptidase (EC 3.4.24.11) inhibition blunts endothelin-1 production in cirrhotic rat livers: physiopathological implications
G. Sansòe, M. Aragno, A. Smedile, M. Rizzetto, M. Parola - Turin

N. 7 One-year mortality rate in patients with stage 3 and 4 cirrhosis: the Italian Association for the Study of Liver (AISF)-EPasco prospective multicentre study

N. 8 Inhibitory control test does not identify the patients at risk of developing overt hepatic encephalopathy (HE) in an italian population of cirrhotic patients
L. Ridola, C. Pasquale, I. Pentassuglio, S. Nardelli, M. Trezza, C. Marzano, M. Merli, O. Riggio - Rome

N. 9 Incomplete reversal of cognitive dysfunction after liver transplantation in individuals who had had overt hepatic encephalopathy before liver transplantation
F. Campagna, A. Biancardi, S. Montagnese, P. Angeli, D. Mapelli, C. Pod, S. Schiiff, U. Cillo, A. Gatta, P. Amadio - Padua

N. 10 Pharmacological antagonism of endocannabinoid CB1 receptor ameliorates liver fibrosis in a rat model of advanced cirrhosis
F.A. Giannone, M. Domenicali, M. Baldassarre, G. Di Pompo, M. Bernardi, P. Caraceni - Bologna

N. 11 Anticoagulant treatment for not neoplastic portal vein thrombosis in patients with liver cirrhosis and esophageal varices.
G. Butera, F. Simone, A. Iacobò, V. Calvaruso, V. Di Marco, A. Crazi - Palermo

N. 12 Bacterial infections in cirrhosis are associated with a poor prognosis that is not reflected by mel'd and ukeld scores

N. 13 Prevalence of spontaneous hepatic-to-hepatic venous shunts in cirrhotic patients with portal hypertension
L. Bellis, R. Guarisco, F. Paglia, L. Spilabottò, O. Dell’Unto, D. Bavoñottò, A. Bracciò, C. Puotì Marino

N. 14 Algorythm for the treatment of portal (PVT) and splancnic veins thrombosis (SVT) in patients with liver cirrhosis
N. 15 Reactivation of hepatitis B or C in patients with IBD, undergoing immunosuppressive therapy. An Italian retrospective multicentre study

N. 16 Effectiveness of Entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients

N. 17 Phylogenetic analysis of HBV infection in Sicily: is the epidemiology changing?
D. Ferraro, N. Urone, V. Di Marco, B. Cacopardo, A. Iacò, M. Gussio, S. Magliocco, A. Craxì, R. Di Stefano - Palermo, Catania

N. 18 Neutrophil phagocytic dysfunction in stable cirrhosis is independent of bacterial DNA and associated with increased expression of TLR-4
G. Tritto, R. Francés, N. Shah, V. Stadlbauer, N. Davies, R. Mookerjee, J. Such, R. Jalan - London (UK), Alicante (Spain), Naples

N. 19 Role of advanced cytology for the diagnosis of malignant bile duct strictures in patients with jaundice.
M. Sartori, M. Orcello, F. Martino, M. Ballarè, E. Garelio, R. Boldorini, A. Paganotti, S. Carmagnola, S. Andorno, M. Del Piano - Novara

N. 20 Natural history and multimodality treatment of early hepatocellular carcinoma prospectively detected in cirrhotic patients under surveillance
A. Sangiovanni, C. Della Corte, M.A. Manini, S. Vavassori, M. Iavarone, R. Romeo, M. Fraquelli, L.V. Forzenigo, G. Ronchi, A. Aghemo, M. Colombo - Milan, Pavia

N. 21 HCV enhances hepatoma cells invasiveness regulating focal adhesion molecules
A. Alisi, M. Arciello, A. Mancinetti, S. Anticoli, C. Balsano - Rome, L'Aquila

N. 22 Field practice with sorafenib in advanced HCC: effectiveness confirmed, tolerability reduced but usually manageable, compared to registration trials
M. Iavarone, A. Sangiovanni, S. Vavassori, R. Romeo, M. Colombo - Milan

N. 23 Hypoxia up-regulates SERPIN B3 in hepatic cancer cells by a HIF-2α – dependent mechanism
C. Paternostro, C. Turato, S. Quarta, S. Cannito, E. David, S. Colombatto, A. Biasiolo, M. Villano, P. Pontisso, M. Parola - Turin, Padua

N. 24 ERK5 is overexpressed in hepatocellular carcinoma (HCC), and is modulated by soluble factors in HCC cells
E. Rovida, N. Navari, S. Cannito, P. Dello Sbarba, M. Parola, F. Marra - Turin, Florence

N. 25 Three cm or less single hepatocellular carcinoma: a randomized controlled trial comparing percutaneous ethanol injection versus percutaneous radiofrequency ablation

N. 26 Efficacy of superselective TACE in treatment of HCC

N. 27 Notch signalling controls proliferation and senescence of human hepatocellular carcinoma
M. Minguzzi, C. Giovannini, L. Gramantieri, F. Fornari, P. Chieco, F. Piscaglia, L. Bolondi - Bologna

N. 28 The role of small Intestinal bacterial overgrowth on development of diarrhea in HCC patients treated with Sorafenib

N. 29 Insulin resistance does not predict a response to pegylated interferon plus ribavirin in chronic hepatitis C patients: a sub-analysis of the mist study
N. 30 Treatment of chronic hepatitis C with peg-IFN-α plus ribavirin don't alter fluoxetine disposal
G. Soardo, L. Franceschi, D. Donnini, M. Furlanut, L. Sechi - Udine

N. 31 Could more genotype-1 HCV patients complete future STAT-C regimens in real practice?
R. Termini, H.F. Zhang, D. Budd, M. Garau Cologno Monzese, Raritan (NJ, USA)

N. 32 Liver Expression of RBP4 Correlates with Liver Damage in Chronic Hepatitis C and in Nonalcoholic Fatty Liver Disease.

N. 33 Long-term outcome of HCV-related mixed cryoglobulinemia in patients achieving sustained viral response (SVR) after antiviral therapy

N. 34 Long-term evaluation of fibrosis by Transient Elastography in patients clearing HCV on antiviral therapy
V. Calvaruso, P.L. Almasio, P. Pizzillo, R. Di Stefano, V. Di Marco, C. Cottone, S. Petta, A. Calì, A. Craxì - Palermo

N. 35 Immunology in liver transplantation for end-stage HCV-related liver disease: a preliminary study on T regulatory cell kinetics

N. 36 Treatment with interferon (IFN) plus ribavirin (RBV) of β-thalassemic patients with HCV chronic hepatitis
A. De Santis, F. Cristofari, F. Giubilo, C. Bassanelli, A.A. Losardo, P. Pugliese, C. Iegri, F. Gigliotti, A.F. Attili - Rome

N. 37 Accurate individualization of Peg-IFN+RBV treatment duration by HCV infected cell decline computed in the 1st month of therapy

N. 38 Hepcidin expression at hepatic, serum and urinary level in subjects with different iron phenotypes
M. Pozzi, S. Pelucchi, P. Trombini, R. Mariani, S. Coletti, S. Vanessi, E. Nemeth, N. Tomosugi, D. Barisani, A. Piperno - Milan, Monza, Los Angeles (CA, USA), Ishikawa (Japan)

N. 39 Homozygosity for the PNPLA3/Adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

N. 40 Inflammatory molecules involved in non-alcoholic steatohepatitis in rats fed different diets
N. Panera, A. Alisi, A. Masotti, L. Da Sacco, M. Pezzullo, R. Devito, G. Bruscalupi, S. Leoni, M. Manco, V. Nobili - Rome

N. 41 Non alcoholic fatty liver disease and aging. Prevalence and associated factors

N. 42 Liver steatosis in normal weight subjects: preliminary results from a large observational study (Bagnacavallo study)

N. 43 Coffee and its components in a rat model of NASH
D.C. Amoruso, F. Morisco, G. Mazzone, M.T. Ribecce, P. Vitaglione, V. Fogliano, N. Caporaso, G. D’Argenio - Naples

N. 44 Hepatic retinol binding protein 4 (RBP-4) levels are significantly related to the steatohepatitis grade (compromission) but not with HCV infection
M. Persico, M. Pancione, A. Fucci, L. Sabatino, D. Pasquali, M. Masarone, V. La Mura, E. Pesico, R. Vecchione, V. Colantuoni - Naples, Benevento

N. 45 NAFLD prevalence in new diagnosed cases of liver disease in southern Italy: results of a prospective multicentric study
M. Masarone on behalf of the SCIROCCO study group - Naples
N. 46 Clinical characteristics and outcomes by ethnicity and race of patients listed for liver transplantation for primary sclerosing cholangitis
C.L. Bowlus, C.-S. Li, C. Selmi - Davis (CA, USA), Milan

N. 47 Regulation of liver graft cholesterol synthesis and uptake affects the outcome of human liver transplantation

N. 48 Influence of donor-recipient variables on short term patient survival following liver transplantation (LT)

N. 49 A modified child-turcotte-pugh (CTP) for selection of candidates to liver transplantation (LT) with low model for end-stage liver disease score (MELD)
3rd A.I.S.F. POST-MEETING COURSE

"Reading Radiological Images in Liver Diseases"
"Lettura delle immagini radiologiche per l'epatologo"
Auditorium, Centro Congressi Frentani - Via dei Frentani, 4
Rome, February 27th, 2010

Course Directors: F. Piscaglia, Bologna and P. Toniutto, Udine

Saturday, February 27th

08.30-08.45  Registration of Participants

08.45-09.00  Course Presentation
F. Piscaglia & P. Toniutto

Session I
TC, RM of the liver
Chairpersons: C. Catalano, Rome - F. Piscaglia, Bologna

09.00-09.25  TC: equipment, acquisition modalities and contrast patterns of focal liver lesions
C. Zuiani, Udine

09.25-09.50  MRI: equipment, acquisition modalities, contrast agents and diagnostic patterns of focal liver lesions
G. Brancatelli, Palermo

09.50-10.40  Case presentations and Discussion

10.40-11.00  Break

Session II
Angiography of the liver and bile tract
Chairpersons: V. Cantisani, Rome - P. Toniutto, Udine

11.00-11.25  Angiography and TACE. Diagnostic patterns of vascular and neoplastic disease and how to read films of treatment procedures
E. Giampalma, Bologna

11.25-11.45  ERCP – M. Mutignani, Rome

11.45-12.05  PTC – A. Doriguzzi Breatta, Turin

12.05-12.25  Cholangio MRI – R. Manfredi, Verona

12.25-12.55  Case presentations and Discussion

12.55  Closure of the Course